Neurocrine Biosciences reported $348.3M in Operating Expenses for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 8821M 991M
Acadia Pharmaceuticals ACAD:US $ 228.48M 53.07M
Acorda Therapeutics ACOR:US $ 39.24M 9.29M
Agios Pharmaceuticals AGIO:US $ 99.27M 2.91M
Alnylam Pharmaceuticals ALNY:US $ 359.99M 93.1M
Amgen AMGN:US $ 3.74B 804M
Aptinyx Inc APTX:US $ 19.38M 207K
Biogen BIIB:US $ 1921.1M 225.6M
Biomarin Pharmaceutical BMRN:US $ 382.03M 133.66M
Cytokinetics CYTK:US $ 81.7M 4.39M
Enanta Pharmaceuticals ENTA:US $ 52.56M 5.49M
Exelixis EXEL:US $ 272.74M 61.76M
Halozyme Therapeutics HALO:US $ 41.61M 3.86M
IONIS PHARMACEUT IONS:US $ 199.42M 19.98M
Nektar Therapeutics NKTR:US $ 137.92M 598K
Prothena PRTA:US 39.1M 4.83M
Teva Pharmaceutical TEVA:IT 4.37B 352M
Ultragenyx Pharmaceutical RARE:US $ 216.57M 30.61M
Xoma XOMA:US $ 5.17M 408K